Trial Profile
ADO CTCL-3 (Tarado): Multicentric therapy protocol for bexarotene (Targretin) monotherapy in pretreated CTCL stage =Ib with clear assignment to a EORTC-Diagnosis - Tarado
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Bexarotene (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- Acronyms Tarado
- 25 Jan 2013 New trial record